» Articles » PMID: 12555211

Long Term Follow-up After Splenectomy Performed for Immune Thrombocytopenic Purpura (ITP)

Overview
Journal Am J Hematol
Specialty Hematology
Date 2003 Jan 30
PMID 12555211
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Splenectomy is the only treatment of ITP known to have "curative" effects in a substantial fraction of patients. However, the true long-term outcome is uncertain and controversial because published series have not adjusted for the duration of follow-up. This IRB-approved retrospective study included all patients with ITP who underwent splenectomy between 1988-1993 at three major medical centers and required a minimum postoperative 5-year follow-up. Complete response (CR) was defined as all postsplenectomy platelet counts >150 x 10(9)/L without treatment; partial response (PR) as platelet counts > or =50 x 10(9)/L without treatment; and failure as platelet counts <50 x 10(9)/L or receiving therapy after splenectomy. Seventy-five patients identified with ITP underwent splenectomy from 1988 to 1993. Three patients died prior to 5-year follow-up, and 56 of the 72 patients (78%) were evaluable with follow-up for five years or longer, median 7.5 years. The immediate postoperative complete remission rate was 77%; 57% of patients have remained in prolonged CR. Thirty-seven patients (66%) have not required any therapy after splenectomy. Eight patients had platelet counts >150 x 10(9)/L for 4-8.5 years before relapsing; no clear plateau was attained in the remission curve. There was no operative mortality. Ten patients (18%) reported minor postoperative bleeding episodes. No life-threatening infections, significant heart disease, or pulmonary hypertension developed after splenectomy in the 434 patient-years of follow-up. This study helps to define the long-term results of splenectomy for ITP.

Citing Articles

Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature.

Castelli R, Atzori E, Delitala A, Masala S, Micheluzzi V, Ponti E Front Cardiovasc Med. 2025; 12:1508574.

PMID: 40013124 PMC: 11861326. DOI: 10.3389/fcvm.2025.1508574.


Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine.

Latef T, Howard L, Loke C, Tsui E BMJ Case Rep. 2025; 15(9).

PMID: 39901382 PMC: 9442476. DOI: 10.1136/bcr-2022-249477.


Regeneration of Thyroid Glands in the Spleen Restores Homeostasis in Thyroidectomy Mice.

Tian X, Yin Z, Li Z, Wang Z, Xing Z, Liu C Adv Sci (Weinh). 2023; 11(6):e2305913.

PMID: 38059822 PMC: 10853707. DOI: 10.1002/advs.202305913.


Comparison of Response to Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia According to the Presence of Accessory Spleen.

Hindilerden F, Yonal-Hindilerden I, Yenerel M, Nalcaci M, Diz-Kucukkaya R Hematol Rep. 2022; 14(3):222-227.

PMID: 35893154 PMC: 9326767. DOI: 10.3390/hematolrep14030030.


Splenectomy in the management of primary immune-mediated hemolytic anemia and primary immune-mediated thrombocytopenia in dogs.

Bestwick J, Skelly B, Swann J, Glanemann B, Bexfield N, Gkoka Z J Vet Intern Med. 2022; 36(4):1267-1280.

PMID: 35801263 PMC: 9308443. DOI: 10.1111/jvim.16469.